FDA Makes Broad Concessions In Settling Pacira Promotion Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will formally rescind Exparel warning letter and expand labeling to clarify that pain drug is not limited to any specific surgery.